Renewal Of Marketing Authorisation, The Mutual Recognition Secondoprocedura, Of The Medicinal Product For Human Use "montelukast Teva ', Resulting In A Review Printed.

Original Language Title: Rinnovo dell'autorizzazione all'immissione in commercio, secondoprocedura di mutuo riconoscimento, del medicinale per uso umano«Montelukast Teva», con conseguente modifica stampati.

Read the untranslated law here: http://www.gazzettaufficiale.it/atto/serie_generale/caricaArticoloDefault/originario?atto.dataPubblicazioneGazzetta=2015-03-19&atto.codiceRedazionale=15A01895&elenco30giorni=false&atto.tipoProvvedimento=DECRETO

Retrieved February 11, 2015 40/2015 # PV of Medicine determines: MONTELUKAST TEVA packaging: A.I.C. # 040673 016 «10 mg film-coated tablets» 7 tablets in AL/AL A.I.C. # 040673 028 «10 mg film-coated tablets» 14 tablets in AL/AL A.I.C. # 040673 030 «10 mg film-coated tablets» 15 tablets in AL/AL A.I.C. # 040673 042 «10 mg film-coated tablets» 20 tablets in AL/AL A.I.C. # 040673 055 «10 mg film-coated tablets» 28 tablets in AL/AL A.I.C. # 040673 067 «10 mg film-coated tablets» 30 tablets in AL/AL A.I.C. # 040673 079 «10 mg film-coated tablets» 50 tablets in AL/AL A.I.C. # 040673 081 «10 mg film-coated tablets» 56 tablets in AL/AL A.I.C. # 040673 093 «10 mg film-coated tablets» 60 tablets in AL/AL A.I.C. # 040673 105 ' 10 mg film-coated tablets» 90 tablets in AL/AL A.I.C. # 040673 117 «10 mg film-coated tablets» 98 tablets in AL/AL A.I.C. # 040673 129 «10 mg film-coated tablets» 100 tablets in AL/AL A.I.C. # 040673 131 ' 10 mg film-coated tablets» 7 tablets in AL/AL calendar Pack;
A.I.C. # 040673 143 "10 mg film-coated tablets» 14 tablets in al/al calendar Pack;
A.I.C. # 040673 156 «10 mg film-coated tablets» 28 tablets in AL/AL A.I.C. # 040673 168 «10 mg film-coated tablets» 56 tablets in AL/AL A.I.C. # 040673 170 «10 mg film-coated tablets» 98 tablets in AL/AL Mah: Teva Italy S.R.L.
Mutual recognition procedure DK/H/1332/001/R/001.
Ending on September 24, 2013 is renewed, with unlimited validity, the marketing authorisation subject to amendment of the summary of product characteristics, package leaflet and labelling and on condition that, on the date of entry into force of this determination, the requirements of quality, safety and efficacy are still present.
Changes must be made immediately to the summary of the product characteristics as per the package leaflet and labelling no later than six months after its publication in the Official Gazette of the Italian Republic of this determination.
In accordance with art. 80, paragraphs 1 and 3, of Legislative Decree No 219 April 24, 2006 and s leaflet and labels must be written in Italian and, limited to medicinal products marketed in the province of Bolzano, in German. The mAh avails itself of the complementary use of foreign languages, must give prior notice to the AIFA and keep available the certified translation of German texts and/or in another foreign language. In case of non-compliance with the provisions on the labelling and package leaflet shall apply sanctions under art. 82 of the Decree.
Both lots already products as of the date of publication in the official journal of the Italian Republic of this determination that the batches produced during the period referred to in article 2, paragraph 2, of the aforementioned determination, which did not indicate the changes authorized, can be kept on the market until the expiration date printed on the label of the medicine. Pharmacists are required to deliver the package leaflet updated users as from the end of 30 days from the date of publication in the Official Gazette of the Italian Republic of this determination. The mAh makes accessible to pharmacist leaflet updated within the same timeframe.
This determination takes effect from the day following that of its publication in the official journal of the Italian Republic and will be notified to the company holder of the marketing authorisation of the medicinal product.